Clearside Biomedical's Financial Performance in the Biopharmaceutical Industry

Core Insights - Clearside Biomedical, Inc. is a biopharmaceutical company focused on developing therapies for eye diseases using its proprietary SCS Microinjector for drug delivery [1] - The company faces competition from other biopharmaceutical firms such as Cidara Therapeutics, Selecta Biosciences, vTv Therapeutics, and Corvus Pharmaceuticals [1] Financial Performance - Clearside Biomedical has a Return on Invested Capital (ROIC) of -177.13%, which is significantly lower than its Weighted Average Cost of Capital (WACC) of 17.35% [2] - The negative ROIC indicates that the company is not generating positive returns on its invested capital, with a ROIC to WACC ratio of -10.21 highlighting inefficiencies in capital utilization [2] Peer Comparison - Cidara Therapeutics has a ROIC of -46.99% and a WACC of 10.99%, resulting in a less severe ROIC to WACC ratio of -4.27 compared to Clearside [3] - Selecta Biosciences shows a positive ROIC of 6.80% and a WACC of 8.38%, leading to a positive ROIC to WACC ratio of 0.81, indicating better capital efficiency [4] - vTv Therapeutics and Corvus Pharmaceuticals have negative ROIC to WACC ratios of -19.61 and -7.99, respectively, indicating challenges in generating returns above their cost of capital [4]